ClinicalTrials.gg
RecruitingNCT07629843IPV-1940Updated Oct 16, 2026

Patient Satisfaction, Safety, and Efficacy of Endovenous Laser Treatment for Saphenous Veins and Varicose Veins

An observational study in Saphenous Vein Injury, sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche · Observational

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 16, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
155
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the post-operative patient satisfaction on the treatment of saphenous veins and varicose veins outside the operating theater under strict local anesthesia with a 1940 nm laser via the Venous Treatment Satisfaction Questionnaire early.

Read the detailed description

This is a non-interventional, prospective, non-randomized, descriptive, and multicenter study.

The study will be conducted by vascular physicians practicing at the Institute of Vascular Pathology of the Geoffroy Saint-Hilaire Private Hospital or La Muette Clinic (Paris).

The study population will be composed of adult patients receiving routine care for Endovenous Laser Ablation of primary or recurrent saphenous vein (great saphenous vein, small saphenous vein or anterior saphenous vein) outside the operating theater under strict local anesthesia.

02

Conditions studied

  • Saphenous Vein Injury
03

In context

Lead sponsor

GCS Ramsay Santé pour l'Enseignement et la Recherche is the lead sponsor of 208 studies on the registry; 100 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will be composed of adult patients receiving routine care for Endovenous Laser Ablation of primary or recurrent saphenous vein (great saphenous vein, small saphenous vein or anterior saphenous vein) outside the operating theater under strict local anesthesia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Endovenous Laser Ablation of a common or recurrent saphenous vein as part of routine care.
  • Clinical, Etiology, Anatomy, Pathophysiology, classification clinical stage.
  • Ability to understand the study objectives and complete questionnaires in French.
  • Patient has been informed and has verbally indicated their non-opposition to participating in the research.

Exclusion criteria

Exclusion Criteria:

  • Endovenous Laser Ablation not feasible for technical reasons, particularly if the vein is too "bent" or there are endoluminal obstacles.
  • Episode of deep vein thrombosis less than 3 months ago or of superficial vein thrombosis less than 6 weeks ago.
  • Active cancer.
  • Geographical distance incompatible with study follow-up, according to the investigator's judgment.
  • Patients currently participating or having participated in research within the previous 3 months.
  • Persons covered by articles L1121-5 to L1121-8 of the French Public Health Code (corresponds to all protected persons: pregnant women, women in labor, breastfeeding mothers, persons deprived of liberty by judicial or administrative decision, persons subject to a legal protection measure).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
155 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Primary or recurrent saphenous vein

    Patients receiving routine care for endovenous laser ablation of the primary or recurrent saphenous vein (great saphenous vein, small saphenous vein or anterior saphenous vein)

    Procedure: Endovenous laser ablation of the primary or recurrent saphenous vein

Interventions

  • ProcedureEndovenous laser ablation of the primary or recurrent saphenous vein

    Treatment of saphenous veins and varicose veins performed outside the operating room strictly under local anesthesia with a 1940 nm laser.

06

What researchers measure

Primary outcomes

  1. Venous Treatment Satisfaction Questionnaire early score

    Evaluate the post-operative patient satisfaction on the treatment of saphenous veins and varicose veins outside the operating theater under strict local anesthesia with a 1940 nm laser via the Venous Treatment Satisfaction Questionnaire early. Scale from 0 to 6 (a high score indicates a positive result).

    Time frame: 12 days

07

Study locations

2 of 2 sites recruiting
  • Institut de Pathologie Vasculaire - Hôpital Privé Geoffroy Saint-Hilaire
    Paris, 75005, France
    Recruiting
  • Clinique de la Muette
    Paris, 75116, France
    Recruiting
    • Anne-Sophie LENSEL, MD · Contact
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Jun 2028, 20 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 5, 2026
StartActual
Oct 1, 2026was Sep 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
1 site added. Institut de Pathologie Vasculaire - Hôpital Privé Geoffroy Saint-Hilaire is now Recruiting
Show site
  • Clinique de la Muette · Paris, France
Oct 16, 2026
Start date
Sep 2026→Oct 1, 2026 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    1 site added. Institut de Pathologie Vasculaire - Hôpital Privé Geoffroy Saint-Hilaire is now Recruiting
    Show site
    • Clinique de la Muette · Paris, France
    Start date Sep 2026→Oct 1, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07629843
Collaborators
Euraxi Pharma
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
Oct 1, 2026
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Claudine HAMEL-DESNOS, MD
Contact
claudine.hamel-desnos@wanadoo.fr
144085838 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion